顺铂对人肺腺癌细胞作用与ERCC1、Bcl-2表达的相关性研究 |
| |
引用本文: | 金艺凤,何贝,刘东华,王莹. 顺铂对人肺腺癌细胞作用与ERCC1、Bcl-2表达的相关性研究[J]. 中国临床药理学与治疗学, 2013, 18(7): 764-768 |
| |
作者姓名: | 金艺凤 何贝 刘东华 王莹 |
| |
作者单位: | 1. 皖南医学院附属弋矶山医院呼吸内科,芜湖241001,安徽 2. 安庆市立医院呼吸内科,安庆246000,安徽 |
| |
基金项目: | 安徽省高等学校省级科学研究项目(KJ20118195) |
| |
摘 要: | 目的:探讨ERCC1、Bcl-2表达与顺铂作用的关系,进而推测ERCC1、Bcl-2在顺铂耐药中的作用.方法:选择人肺腺癌细胞A549及其耐DDP细胞株A549/DDP作为研究对象,采用MTT法检测A549/DDP细胞耐药指数;免疫细胞化学方法、RT-PCR方法检测不同浓度、不同作用时间干预后细胞中ERCC1、Bcl-2的表达.结果:10μg/mL DDP作用12 h,A549细胞中ER-CC1、Bcl-2 mRNA表达开始增高,随着作用时间的延长,ERCC1、Bcl-2 mRNA的表达逐渐增高,在72 h表达最强.浓度为5μg/mL的DDP即可刺激A549细胞中ERCC1、Bcl-2 mRNA表达水平上升,随着DDP浓度的增加,其表达水平逐渐上升,ERCC1民mRNA表达水平在20μg/mL组达到高峰.与亲本细胞相比,A549/DDP中ERCC1、Bcl-2表达明显增高.结论:随着顺铂作用时间的延长和浓度的增加,A549细胞中ERCC1、Bcl-2 mRNA和蛋白的表达量增加,推测ERCC1、Bcl-2可能参与了顺铂继发耐药的形成.
|
关 键 词: | 肺癌 顺铂 耐药 ERCC1 Bcl-2 |
Relationship between ERCCI, Bcl-2 expression and cisplatin interven-tion in human lung adenocarcinoma cell lines |
| |
Affiliation: | JIN Yi-feng, HE Bei , LIU Dong-hua, WAN Ying(1 Department of Respiratory, the Affiliated Yijishan Hospital of 241001 ,Anhui, China ; 2 Department of Respiratory, Anqing City hui, China Wannan Medical College , Wuhu Hospital , Anqing 241001 ,An-hui,China) |
| |
Abstract: | Objcetive The excision repair cross-complementing gene 1(ERCC1) and Bcl-2 are reported to be related to cisplatin resistance in tumor cells.The aim is to confirm the relationship between ERCC1,Bcl-2 and cisplatin resistance in human lung adenocarcinoma cell lines. Methods A549 and A549/DDP cell lines were treated with 10ug/ml cisplatin for 12,24,48,72h,or treated with 5,10,20,40 ug/ml cisplatin for 24h respectively. Then the resistance of A549/DDP cells was measured by MTT assay. The expression of ERCC1,Bcl-2 mRNA and protein was measured by immunocytohistology SABC assay and PR-PCR respectively. Results After treating with 10ug/ml cisplatin for 12h, up-regulation of ERCC1,Bcl-2 mRNA and protein was observed in A549 cells; Then reached the peak levels in 72h group. After treating with 5ug/ml cisplatin for 24h, up-regulation of ERCC1, Bcl-2 mRNA and protein was observed in A549 cells.When treated with 20ug/ml cisplatin for 24h,the ERCC1 mRNA and protein reached the peak levels. Comparing with the parental cells, ERCC1and Bcl-2 expression increased obvious in A549/DDP cells. Conclusion Up-regulation of ERCC1, Bcl-2 exprission can be induced by low-dose cisplatin in human lung adenocarcinoma cell line A549,and ERCC1and Bcl-2 may play roles in cisplatin acquired resistance. |
| |
Keywords: | Lung cancer Cisplatin Resist-ance ERCC1 Bcl-2 |
本文献已被 维普 万方数据 等数据库收录! |
|